Diligence memo · auto-generated · as of July 2, 2026

Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Ligand Pharmaceuticals Inc operates in Pharmaceuticals, based in LA JOLLA.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Ligand Pharmaceuticals Inc has raised $85M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $85M on 2016-01-08.

Most recent recorded round closed around 2016-01-08.

Valuation (modeled)modeled

Provath models Ligand Pharmaceuticals Inc at approximately $3.0B (range $278M–$7.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.29× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era. Within the normal band (129% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 10.5 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 89% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 97% of those peers.

Closest niche peers: Amplyx Pharmaceuticals, Inc., Homology Medicines, Inc., KSQ Therapeutics, Inc., TP Therapeutics, Inc., Milestone Pharmaceuticals Inc..

Peoplefiled

12 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.